You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 生物疫苗板塊走強 新冠疫苗加強針混打啟動
格隆匯 02-21 14:38
格隆匯2月21日丨生物疫苗板塊走強,其中未名醫藥漲停,麗珠集團漲超6.5%,賽升藥業漲約5%,力生製藥、仁和藥業、華北製藥漲超3%,海南海藥漲2.8%,科前生物漲約2.5%,一品紅漲2.3%,康希諾漲1%,智飛生物跟漲。近日,經國務院聯防聯控機制批准,國家衞生健康委已開始部署序貫加強免疫接種。 此前,凡全程接種國藥中生北京公司、北京科興公司、國藥中生武漢公司滅活疫苗或天津康希諾公司的腺病毒載體疫苗滿6個月18歲以上的目標人羣,可進行一劑次同源加強免疫,也就是用原疫苗進行加強。 序貫加強免疫策略實施後,完成全程接種上述三種滅活疫苗的目標人羣,還可以選擇智飛龍科馬的重組蛋白疫苗或康希諾的腺病毒載體疫苗進行序貫加強免疫。對於目標人羣來説,同源加強免疫接種和序貫加強免疫選擇一種即可。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account